Skip to main content
NeurAxis logo

NeurAxis

Carmel, Indiana

  • Neuromodulation
  • Chronic pain

NeurAxis is a commercial-stage medical technology company developing and commercializing neuromodulation therapies for chronic and debilitating conditions. Its work focuses on disorders of gut-brain interaction, including functional abdominal pain associated with IBS and functional dyspepsia, with therapies for pediatric, adolescent, and adult patients.

Raised
$14.1M
Investor
1
Employees
11–50

reccy insights

Recent highlights

NeurAxis expanded its commercial access and reimbursement footing through several milestones. On January 21, 2025, it announced medical policy coverage with a prominent insurer reaching more than five million covered lives across multiple states. On December 1, 2025, the company secured a Veterans Affairs Federal Supply Schedule contract, creating a route for IB-Stim into the VA health system. A Category I CPT code for IB-Stim took effect on January 1, 2026, and NeurAxis announced the milestone on January 8, establishing a permanent coding and reimbursement pathway. The company began commercializing its FDA-cleared RED device in May 2025. Financial headlines reported 22% revenue growth in Q3 2025 and 79.5% revenue growth in Q1 2026, alongside a narrower net loss in Q1. A May 2026 report also highlighted expanded coverage and pediatric and VA market growth. In leadership, NeurAxis appointed Timothy Henrichs Chief Financial Officer on January 31, 2024. These developments indicate continued work on coverage, clinical adoption and product commercialization, while the Q1 2026 financial coverage also noted going-concern risks.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes NeurAxis distinct

  1. 01Focuses on targeted neuromodulation therapies for disorders of gut-brain interaction and related chronic abdominal pain.
  2. 02Developed IB-Stim®, an FDA-cleared percutaneous electrical nerve field stimulation technology.
  3. 03Builds on clinical evidence and conducts additional PENFS trials for pediatric conditions.
  4. 04Reports broad insurance coverage representing more than 100 million covered lives for its therapies.
  5. 05Combines medical technology development with clinical research, regulatory expertise and commercial operations.

Technology & products4

  • IB-Stim

    A non-surgical, peripherally placed neuromodulation device that delivers electrical impulses to cranial nerve bundles in the ear to treat functional abdominal pain associated with IBS and functional dyspepsia.

  • Percutaneous Electrical Nerve Field Stimulation (PENFS)

    NeurAxis’ neuromodulation technology that applies electrical stimulation through peripheral nerve fields to address chronic pain and other disorders of the gut-brain interaction.

  • RED – Rectal Expulsion Device

    A point-of-care screening device for chronic constipation that assesses evacuation disorders, pelvic floor dysfunction and rectal hypersensitivity without requiring major capital equipment.

Recent updates4

  • Jan 8, 2026Product launch

    NeurAxis secured an AMA Category I CPT code for its IB-Stim PENFS therapy, creating a permanent coding and reimbursement pathway intended to support broader clinical adoption.

    globenewswire.com
  • Dec 1, 2025Partnership

    NeurAxis secured a Veterans Affairs Federal Supply Schedule contract, establishing a federal contracting route for IB-Stim in the VA health system.

    globenewswire.com
  • May 12, 2025Product launch

    NeurAxis began commercializing its newly FDA-cleared RED device, designed to simplify anorectal function testing.

    globenewswire.com

In the Cortex

Funding

$14.1M disclosed
  • Convertible note financing
    $6.1MLed by Inspire Health Alliance
  • Convertible note financing
    $3MLed by undisclosed healthcare-focused fund
  • Registered direct offering
    $5M
Latest valuation $36,660,5401 investorInvestors: Flagstaff International

Similar companies

About NeurAxis

Products
IB-Stim, Percutaneous Electrical Nerve Field Stimulation (PENFS), RED – Rectal Expulsion Device, NeurAxis Certification and Provider Training
Leadership
Timothy Henrichs, CFO
Focus areas
Medtech, neuromodulation, medical devices, penfs, gastroenterology, pediatric health, chronic pain, clinical research
Headquarters
Carmel, Indiana
Employees
11–50